This benefit appears to stem from multiple mechanisms: weight loss, improved blood sugar control, reduced inflammation, and modest improvements in blood pressure
Eligibility Criteria Your PCP Will Evaluate PCPs screen for GLP-1 appropriateness using standardized criteria: BMI 30, or BMI 27 with weight-related comorbidities (diabetes, hypertension, sleep apnea)
Quercetin suppresses apoptosis of chondrocytes induced by IL-1 via inactivation of p38 MAPK signaling pathway
In order for GLP-1s to gain FDA approval for this use, they must go through two well-designed (large, randomized, double-blind, placebo-controlled) phase 3 clinical trials that, ideally, run for 6 to 12 months
Its common to have questions or periods of uncertainty
At Flawless MedSpa, we support your Semaglutide GLP-1 treatment with comprehensive guidance, regular follow-up appointments, and personalized consultations